Shenzhen Jindu Biomedical Technology

Shenzhen Jindu Biomedical Technology Co., Ltd., operating as OxTium Technology, is a company specializing in AI-driven bioscience. The company was founded by Yongcheng Jin, who holds a Ph.D. in Biomedical Engineering from the University of Oxford.

OxTium provides end-to-end solutions through two main offerings: the BioFord™ Intelligent Research Ecosystem and the GeneLLM® Cross-modal Analysis System. BioFord™ is a cloud-native platform for life science research, while GeneLLM® is a pre-trained, multi-omics large language model framework designed to interpret biological data. These platforms are applied across several sectors, including precision diagnostics, industrial biomanufacturing, genomic breeding, and environmental bioengineering. The firm's business model includes providing bioinformatics computing services and AI algorithm development.

The company has formed strategic partnerships with organizations such as BGI Group and PUMCH Cancer Center. In June 2024, OxTium established a Joint Medical AI Innovation Center with MGI Tech, a subsidiary of BGI Group, at the China National GeneBank. The company and its team have been recognized with several awards, including an Outstanding Project Award at the 13th China Innovation and Entrepreneurship Competition in December 2024 and an Excellence Award at the Maker Beijing Innovation and Entrepreneurship Competition in October 2023.

Keywords: AI bioscience, computational intelligence, BioFord, GeneLLM, multi-omics, large language model, precision diagnostics, genomic breeding, bioinformatics, environmental bioengineering, life sciences AI, biomanufacturing, biomedical engineering, intelligent research ecosystem, cross-modal analysis